EA201792025A1 - Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf - Google Patents

Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf

Info

Publication number
EA201792025A1
EA201792025A1 EA201792025A EA201792025A EA201792025A1 EA 201792025 A1 EA201792025 A1 EA 201792025A1 EA 201792025 A EA201792025 A EA 201792025A EA 201792025 A EA201792025 A EA 201792025A EA 201792025 A1 EA201792025 A1 EA 201792025A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crr
heterocyclic compounds
tricyclic heterocyclic
tnf inhibitors
compounds applicable
Prior art date
Application number
EA201792025A
Other languages
English (en)
Other versions
EA032314B1 (ru
Inventor
Стивен Т. Вроблески
Грегори Д. Браун
Шуцюнь Линь
Цзиньву Дуань
Чжуньхуэй Лу
Т. Г. Мурали Дхар
Хай-Юнь Сяо
Эндрю Дж. Теббен
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201792025A1 publication Critical patent/EA201792025A1/ru
Publication of EA032314B1 publication Critical patent/EA032314B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Раскрываются соединения формулы (I)или их соль, в которых X представляет собой N; W представляет собой -(CRR)-, -(CRR)-Y-(CRR)-, -Y-(CRR)-Y-, -CRR-Y-(CRR)-Y-, -Y-(CRR)-Y-CRR-; a Y, R, R, R, R, R, R, x и у определяются в настоящем документе. Также раскрываются способы применения таких соединений в качестве модуляторов TNFα, а также фармацевтические композиции, содержащие такие соединения. Данные соединения применимы при лечении воспалительных и аутоиммунных заболеваний.
EA201792025A 2015-03-18 2016-03-17 Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf EA032314B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134779P 2015-03-18 2015-03-18
PCT/US2016/022738 WO2016149437A1 (en) 2015-03-18 2016-03-17 Tricyclic heterocyclic compounds useful as inhibitors of tnf

Publications (2)

Publication Number Publication Date
EA201792025A1 true EA201792025A1 (ru) 2018-01-31
EA032314B1 EA032314B1 (ru) 2019-05-31

Family

ID=55640933

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792025A EA032314B1 (ru) 2015-03-18 2016-03-17 Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf

Country Status (14)

Country Link
US (1) US10308652B2 (ru)
EP (1) EP3271361B1 (ru)
JP (1) JP6793658B2 (ru)
KR (1) KR102630010B1 (ru)
CN (1) CN107635992B (ru)
AU (1) AU2016233289A1 (ru)
BR (1) BR112017019731A2 (ru)
CA (1) CA2982446A1 (ru)
EA (1) EA032314B1 (ru)
ES (1) ES2797685T3 (ru)
IL (1) IL254520A0 (ru)
MX (1) MX2017011433A (ru)
SG (1) SG11201707471RA (ru)
WO (1) WO2016149437A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6779899B2 (ja) 2015-03-18 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｎｆ阻害剤として有用なヘテロ環式化合物
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
US10953019B2 (en) 2017-03-15 2021-03-23 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
US20050113397A1 (en) 2002-01-31 2005-05-26 Makoto Takemura Imidazo[1,2-a]pyridine derivative
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6359008B2 (ja) 2012-06-11 2018-07-18 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ−アルファ調節ベンゾイミダゾール
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
ES2603931T3 (es) * 2012-11-07 2017-03-02 F. Hoffmann-La Roche Ag Compuestos de triazolo
ES2529865B8 (es) * 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2809535T3 (es) 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
CA2931589C (en) 2013-12-09 2022-01-04 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SI3204386T1 (sl) 2014-10-06 2021-08-31 Signal Pharmaceuticals, Llc Substituirane spojine aminopurina, njihove sestave in načini zdravljenja v povezavi z njimi
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
JP6779899B2 (ja) 2015-03-18 2020-11-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｎｆ阻害剤として有用なヘテロ環式化合物
US9856253B2 (en) * 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
CA2980100A1 (en) * 2015-05-04 2016-11-10 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Also Published As

Publication number Publication date
WO2016149437A1 (en) 2016-09-22
EA032314B1 (ru) 2019-05-31
MX2017011433A (es) 2017-11-10
US20180111937A1 (en) 2018-04-26
IL254520A0 (en) 2017-11-30
JP6793658B2 (ja) 2020-12-02
KR20170129811A (ko) 2017-11-27
CN107635992A (zh) 2018-01-26
US10308652B2 (en) 2019-06-04
SG11201707471RA (en) 2017-10-30
AU2016233289A1 (en) 2017-11-09
ES2797685T3 (es) 2020-12-03
EP3271361A1 (en) 2018-01-24
EP3271361B1 (en) 2020-04-22
JP2018508554A (ja) 2018-03-29
BR112017019731A2 (pt) 2018-05-22
KR102630010B1 (ko) 2024-01-25
CA2982446A1 (en) 2016-09-22
CN107635992B (zh) 2020-05-22

Similar Documents

Publication Publication Date Title
EA201792025A1 (ru) Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf
EA201792054A1 (ru) Гетероциклические соединения, применимые в качестве ингибиторов tnf
EA201890165A1 (ru) Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA201990048A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ
EA201990169A1 (ru) Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA202091484A1 (ru) 4-азаиндольные соединения
EA201790740A1 (ru) Индолкарбоксамидные соединения
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201792229A1 (ru) Ингибиторы бромодомена
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201992674A1 (ru) Тиенопиридины и бензотиофены в качестве ингибиторов irak4
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
EA201890421A1 (ru) Циклические соединения, пригодные в качестве модуляторов tnf-альфа
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU